Cumberland Pharmaceuticals Retained Earnings 2011-2025 | CPIX

Retained earnings — this is the portion of a company’s net profit that has not been distributed to shareholders as dividends but remains at the company’s disposal for future use. It is also referred to as retained income or accumulated earnings.

Possible uses include

reinvestment in development (R&D, equipment, marketing)
debt repayment
acquisition of other companies
creation of reserves for the future

A high level of retained earnings indicates that the company is in a growth phase, accumulating capital and prioritizing reinvestment over dividend payouts. Conversely, low or negative retained earnings may suggest either a generous dividend policy, in which all profits are distributed to shareholders, or ongoing losses that reduce the overall financial result.

The presence of retained earnings does not indicate that the company has available cash — it is solely an accounting figure reflecting the accumulated portion of net profit remaining after dividends have been paid. Therefore, it is important for investors to analyze not only the amount of retained earnings, but also how effectively it is used to develop the business, reduce debt, or build financial stability.

Annual Retained Earnings Cumberland Pharmaceuticals

2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-24 M	-17.5 M	-11.2 M	-5.64 M	-2.13 M	1.21 M	4.75 M	11.7 M	18.6 M	19.5 M	18.8 M	16.4 M	18.5 M	12.7 M

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
19.5 M	-24 M	4.41 M

Quarterly Retained Earnings Cumberland Pharmaceuticals

2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-25.4 M	-23.5 M	-22.7 M	-24 M	-22.1 M	-20.5 M	-	-17.5 M	-11.2 M	-10.1 M	-11 M	-11.2 M	-8.77 M	-8.36 M	-7.02 M	-5.64 M	-1.79 M	-736 K	-1.96 M	-2.13 M	-2.13 M	-2.13 M	-2.13 M	1.21 M	2.17 M	1.21 M	4.67 M	4.75 M	4.75 M	4.75 M	4.75 M	11.7 M	11.7 M	11.7 M	11.7 M	18.6 M	18.6 M	18.6 M	18.6 M	19.5 M	19.5 M	19.5 M	19.5 M	18.8 M	18.8 M	18.8 M	18.8 M	16.4 M	16.4 M	16.4 M	16.4 M	18.5 M	18.5 M	18.5 M	18.5 M	12.7 M	12.7 M	12.7 M	12.7 M

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
19.5 M	-25.4 M	4.33 M

Retained Earnings of other stocks in the Drug manufacturers industry

Issuer	Retained Earnings	Price	% 24h	Market Cap	Country
Alimera Sciences ALIM	-418 M	-	-	$ 142 M	USA
Aerie Pharmaceuticals AERI	-1.15 B	-	-	$ 754 M	USA
Canopy Growth Corporation CGC	-10.9 B	$ 1.24	4.21 %	$ 133 M	Canada
AcelRx Pharmaceuticals ACRX	-457 M	-	7.5 %	$ 6.35 M	USA
Adamis Pharmaceuticals Corporation ADMP	-305 M	-	0.86 %	$ 117 M	USA
Cronos Group CRON	1.06 B	$ 2.65	-0.38 %	$ 1.44 B	Canada
Catalent CTLT	-781 M	-	-	$ 11.5 B	USA
Agile Therapeutics AGRX	-423 M	-	10.11 %	$ 58.2 M	USA
DURECT Corporation DRRX	-589 M	-	-	$ 50.1 M	USA
Eagle Pharmaceuticals EGRX	112 M	-	-39.89 %	$ 27.7 M	USA
Aurora Cannabis ACB	-3.59 B	$ 4.48	-0.22 %	$ 86.3 M	Canada
Endo International plc ENDP	-15.4 B	-	-	$ 28.9 M	Irlanda
Zomedica Corp. ZOM	-171 M	-	-0.21 %	$ 98 M	USA
Evoke Pharma EVOK	-123 M	-	-	$ 36.6 M	USA
Calliditas Therapeutics AB (publ) CALT	-1.43 B	-	-0.1 %	$ 2.03 B	Schweden
HEXO Corp. HEXO	-659 M	-	2.45 %	$ 38.1 M	Canada
Zynerba Pharmaceuticals ZYNE	-275 M	-	-	$ 55.5 M	USA
Emergent BioSolutions EBS	-21.8 M	$ 12.41	-0.16 %	$ 635 M	USA
Athenex ATNX	-1.02 B	-	-23.39 %	$ 1.76 M	USA
Avadel Pharmaceuticals plc AVDL	-794 M	$ 21.56	-0.14 %	$ 2.05 B	France
Evolus EOLS	-609 M	$ 6.87	-0.43 %	$ 426 M	USA
Harrow Health HROW	-134 M	$ 49.9	-0.38 %	$ 1.63 B	USA
China Pharma Holdings CPHI	-44 M	$ 1.29	-	$ 22.5 M	China
Neoleukin Therapeutics NLTX	-187 M	-	-	$ 193 M	Canada
OrganiGram Holdings OGI	-145 M	$ 1.77	-1.4 %	$ 402 M	Canada
Organogenesis Holdings ORGO	-40.1 M	$ 5.1	-3.41 %	$ 672 M	USA
Bausch Health Companies BHC	-9.78 B	$ 7.2	0.07 %	$ 2.63 B	Canada
Lannett Company LCI	-596 M	-	1.15 %	$ 7.11 M	USA
Rockwell Medical RMTI	-397 M	$ 0.84	-2.87 %	$ 19.6 M	USA
Pacira BioSciences PCRX	-206 M	$ 26.55	0.16 %	$ 1.23 B	USA
Sundial Growers SNDL	-565 M	$ 1.75	0.87 %	$ 3.37 M	Canada
Sonoma Pharmaceuticals SNOA	-198 M	$ 3.79	4.47 %	$ 4.7 M	USA
PetIQ PETQ	-161 M	-	1.64 %	$ 400 M	USA
Jupiter Wellness JUPW	-115 M	-	-	$ 33.6 M	USA
Perrigo Company plc PRGO	-2.25 B	$ 13.68	-0.98 %	$ 1.88 B	USA
ProPhase Labs PRPH	11.8 M	$ 0.48	-7.5 %	$ 7.61 M	USA
Veru VERU	-295 M	$ 2.42	0.83 %	$ 326 M	USA
Radius Health RDUS	-1.37 B	-	-	$ 1.42 B	USA
cbdMD YCBD	-182 M	$ 1.74	2.35 %	$ 7.5 M	USA
Recro Pharma REPH	-279 M	-	-4.76 %	$ 65.3 M	USA
Relmada Therapeutics RLMD	-561 M	$ 4.4	-2.44 %	$ 132 M	USA
OptiNose OPTN	-720 M	-	-	$ 1.08 B	USA
Assertio Holdings ASRT	-652 M	$ 10.13	1.91 %	$ 720 M	USA
PLx Pharma PLXP	-148 M	-	-27.8 %	$ 2.56 M	USA
Solid Biosciences SLDB	-783 M	$ 5.77	-1.19 %	$ 236 M	USA
SCYNEXIS SCYX	-355 M	$ 0.6	2.9 %	$ 28.7 M	USA
Tricida TCDA	-810 M	-	-	$ 3.25 M	USA
Tilray TLRY	-2.42 B	$ 9.57	-0.27 %	$ 5.91 B	Canada
TherapeuticsMD TXMD	-950 M	$ 1.77	1.63 %	$ 18.5 M	USA